Sign In
Buy WVE
$5.76
+0.0700 (+1.23%)
At Close: Jun 03, 2026
Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reducti
Wave Life Sciences surges after early data shows fat loss benefits from experimental obesity drug
06:05am, Monday, 08'th Dec 2025
Shares of Wave Life Sciences (NASDAQ:WVE) surged more than 126% on Monday after the biotech company reported early clinical data showing its experimental...
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences: Being Realistic, There Is Still So Much To Prove
04:12pm, Friday, 05'th Dec 2025
Wave Life Sciences Ltd. remains a high-risk, high-reward biotech with a unique RNA-based pipeline targeting AATD, obesity, DMD, and Huntington's Disease. I maintain a speculative Buy rating, driven by
Handelsbanken Fonder AB Takes Position in WAVE Life Sciences Ltd. $WVE
05:50am, Monday, 01'st Dec 2025
Handelsbanken Fonder AB purchased a new stake in WAVE Life Sciences Ltd. (NASDAQ: WVE) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commis
Geode Capital Management LLC Grows Stake in WAVE Life Sciences Ltd. $WVE
04:33am, Monday, 01'st Dec 2025
Geode Capital Management LLC lifted its stake in shares of WAVE Life Sciences Ltd. (NASDAQ: WVE) by 6.4% in the undefined quarter, according to the company in its most recent 13F filing with the Secur
These Analysts Revise Their Forecasts On Wave Life Sciences Following Q3 Results
11:46am, Tuesday, 11'th Nov 2025
Wave Life Sciences Ltd (NASDAQ:WVE) reported worse-than-expected third-quarter financial results on Monday.
Wave Life Sciences Ltd. (WVE) Q3 2025 Earnings Call Transcript
08:01pm, Monday, 10'th Nov 2025
Wave Life Sciences Ltd. ( WVE ) Q3 2025 Earnings Call November 10, 2025 8:30 AM EST Company Participants Kate Rausch - Head of Investor Relations Paul Bolno - President, CEO & Director Kyle Moran - CF
Wave Life Sciences (WVE) Reports Q3 Loss, Misses Revenue Estimates
09:45am, Monday, 10'th Nov 2025
Wave Life Sciences (WVE) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.47 per share a year ago.
Wave Life Sciences Reports Third Quarter 2025 Financial Results and Provides Business Update
07:30am, Monday, 10'th Nov 2025
WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed
Wave Life Sciences to Present at Upcoming Investor Conferences
08:30am, Friday, 07'th Nov 2025
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform
Wave Life Sciences to Present Preclinical Data Supporting Therapeutic Potential of WVE-007 for Obesity at ObesityWeek® 2025
08:30pm, Tuesday, 04'th Nov 2025
Presentation will highlight preclinical data supporting the potential of WVE-007 (INHBE GalNAc-siRNA) as a unique approach for the treatment of obesity designed to drive fat loss while preserving musc
Wave Life Sciences Third Quarter 2025 Financial Results Scheduled for November 10, 2025
08:30am, Tuesday, 04'th Nov 2025
CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Ltd. ( WVE ) Spotlight on RNA Editing and RNAi: Pipeline and Clinical Advances in Oligonucleotide Therapeutics October 29, 2025 10:00 AM EDT Company Participants Kate Rausch - Head
Wave Life Sciences (WVE) Soars 8.8%: Is Further Upside Left in the Stock?
06:56am, Thursday, 30'th Oct 2025
Wave Life Sciences (WVE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more s
